- Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK plus non-small cell lung cancer (NSCLC): A sub analysis of ALINAAhn, J. S.; Wu, Y-L.; Dziadziuszko, R.; Barlesi, F.; Nishio, M.; Lee, D. H.; Lee, J-S.; Zhong, W-Z.; Horinouchi, H.; Mao, W.; Lu, S.; Wang, Q.; Yang, C-T.; Korphaisarn, K.; Xu, T.; Bu, L.; Scalori, A.; Petric, P.; Redhead, K.; Solomon, B.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Envonalkib vs crizotinib in treatment-naive advanced ALKpositive NSCLC: A randomized, multicenter, phase III trialZhang, L.; Fang, W.; Min, J.; Yang, N.; Yu, Q.; Cheng, Y.; Zhao, Y.; Li, M.; Chen, H.; Ren, S.; Zhou, J.; Zhuang, W.; Qin, X.; Cao, L.; Yu, Y.; Zhang, J.; He, J.; Feng, J.; Yu, H.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.被引 1
- ctDNA analysis of SAF-189s efficacy in ALK plus advanced nonsmall cell lung cancer (NSCLC)Yang, J-J.; Zhou, J.; Cheng, Y.; Li, M.; Zhao, Q.; Zhang, Z-Y.; Zang, A.; Fan, Y.; Zhou, Y.; Guo, J.; Zheng, Y.; Wu, Z.; Sun, J.; Xiang, X.; Wang, X.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
3被引16阅读
